Eaton Vance Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Eaton Vance Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$41.8M	Buy	60,662 +266	+0.4%	+$167K	0.06%	301
2022 Q2	$35.7M	Buy	60,396 +3,143	+5%	+$2.04M	0.05%	337
2022 Q1	$40M	Buy	57,253 +25,907	+83%	+$16.4M	0.05%	357
2021 Q4	$19.8M	Buy	31,346 +96	+0.3%	+$59K	0.02%	478
2021 Q3	$18.5M	Buy	31,250 +1,939	+7%	+$1.2M	0.03%	446
2021 Q2	$16.4M	Buy	29,311 +438	+2%	+$222K	0.02%	494
2021 Q1	$13.7M	Buy	28,873 +51	+0.2%	+$24.8K	0.02%	504
2020 Q4	$13.9M	Sell	28,822 -1,041	-3%	-$562K	0.02%	471
2020 Q3	$16.7M	Buy	29,863 +1,835	+7%	+$1.11M	0.03%	391
2020 Q2	$17.5M	Buy	28,028 +2,006	+8%	+$1.14M	0.04%	357
2020 Q1	$12.7M	Buy	26,022 +53	+0.2%	+$21.9K	0.03%	363
2019 Q4	$9.75M	Buy	25,969 +4,003	+18%	+$1.35M	0.02%	459
2019 Q3	$6.09M	Buy	21,966 +12	+0.1%	+$3.55K	0.01%	547
2019 Q2	$6.87M	Sell	21,954 -1,407	-6%	-$468K	0.02%	512
2019 Q1	$9.59M	Sell	23,361 -26	-0.1%	-$10.7K	0.02%	420
2018 Q4	$8.73M	Sell	23,387 -174	-0.7%	-$63.7K	0.02%	397
2018 Q3	$9.52M	Hold	23,561	–	–	0.02%	419
2018 Q2	$8.13M	Sell	23,561 -94,619	-80%	-$29.6M	0.02%	433
2018 Q1	$40.7M	Buy	118,180 +54,578	+86%	+$19M	0.05%	270
2017 Q4	$23.9M	Buy	63,602 +5,332	+9%	+$2.16M	0.06%	254
2017 Q3	$26.1M	Buy	58,270 +1,500	+3%	+$714K	0.07%	233
2017 Q2	$27.9M	Buy	56,770 +9,743	+21%	+$4.26M	0.07%	222
2017 Q1	$18.2M	Sell	47,027 -21,401	-31%	-$7.93M	0.05%	260
2016 Q4	$25.1M	Buy	68,428 +4,416	+7%	+$1.68M	0.07%	204
2016 Q3	$25.7M	Sell	64,012 -47,538	-43%	-$19.1M	0.07%	199
2016 Q2	$39M	Buy	111,550 +107,300	+2,525%	+$41.3M	0.11%	167
2016 Q1	$1.53M	Sell	4,250 -50	-1%	-$20.6K	﹤0.01%	603
2015 Q4	$2.33M	Sell	4,300 -655	-13%	-$355K	0.01%	537
2015 Q3	$2.31M	Buy	4,955 +240	+5%	+$129K	0.01%	528
2015 Q2	$2.4M	Buy	4,715 +200	+4%	+$97.6K	0.01%	506
2015 Q1	$2.04M	Buy	+4,515	New	+$1.91M	0.01%	557

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eaton Vance Management's REGN Position: Q3 2022 in Review

Eaton Vance Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.44% in Q3 2022, buying an estimated $167K and bringing the position to 60,662 shares worth $41.8M. The position accounts for 0.06% of the portfolio, ranked #301.

Eaton Vance Management first reported a position in REGN in Q1 2015 and has held it in 31 quarters since. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Eaton Vance Management held 60,662 shares of Regeneron Pharmaceuticals worth $41.8M as of Q3 2022.
Eaton Vance Management bought 266 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $167K.
Regeneron Pharmaceuticals made up 0.06% of Eaton Vance Management's portfolio in Q3 2022, its #301 holding.
Eaton Vance Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 31 quarters since.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.